Brenner Martin 4

What Happened Martin Brenner, listed as a director and identified in the filing as iBio's Chief Executive Officer and Chief Scientific Officer, purchased 12,336 shares of iBio on 2026-03-19 at $2.02 per share, a total transaction value of about $24,919. The Form 4 records the transaction as a purchase (code P), indicating an addition to his holdings rather than a sale.

Key Details

• Transaction date: 2026-03-19; filing date (Form 4): 2026-03-23 (timely within the SEC 2-business-day requirement).
• Price per share: $2.02; shares acquired: 12,336; total value: ~$24,919.
• Transaction type/code: Purchase (P) — listed as open market or private purchase on the filing.
• Shares owned after transaction: Not specified in the provided summary of the Form 4.
• Remarks on the filing: Identifies Brenner as Chief Executive Officer and Chief Scientific Officer. No 10b5-1 plan, tax withholding, or other special footnotes were noted in the provided details.

Context Insider purchases are often watched by retail investors as a potential positive signal, but this was a relatively small-dollar purchase (~$25k) and should be viewed in context with other ownership data and company developments. The filing was submitted within the standard SEC filing window, so there is no late-filing concern for this transaction.